The Latest Breaking News from Seagen

Pfizer stock faces a steep patent cliff, but it's taken steps to offset the coming pressures. Will it be enough?

Shares of Pfizer and Citigroup are languishing near their 52-week lows. However, both stocks offer dividend yields in excess of 5%, and investors might want to buy these two undervalued income plays at current levels.

A bladder cancer treatment combo tied to a quartet of companies — including Seagen — succeeded in a study on Friday, leading SGEN stock to surge.

The Dow Jones rose Friday, bouncing after Thursday's market sell-off. Cathie Wood bought over 1 million shares of Palantir stock.

Slowing Covid treatment sales clipped Pfizer's second quarter revenues, clouding its better-than-expected bottom line beat.

The markets have been on fire the past couple of weeks. While yesterday’s interest hike took some steam out of the markets, these three stocks and their options are unusually active and worthy of consideration.

Activision Blizzard shares rocketed after a court allowed Microsoft to proceed with its acquisition of the video game publisher.

US stock markets delivered stellar returns in the first half of the year and the Nasdaq 100 had its best first-half performance ever. However, Pfizer, whose COVID-19 vaccine made the company a household name recently fell to a 52-week low. Why is Pfizer stock going down and should you buy…

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

The FTC plans to block Amgen's takeover of Horizon. The move reverberated across biotechs, with an HZNP stock crash leading the way.